Will Carroll, Pharm.D., of Sutter Health says future pharmacy leaders need business, finance and AI skills, and health systems need real sponsorship.
News|Articles|October 1, 2005
First-time generic approvals
Clonazepam orally disintegrating tablets 0.125, 0.25, 0.5, 1, and 2 mg (equiv to Klonopin rapidly disintegrating tablets).
Advertisement
Clonazepam orally disintegrating tablets 0.125, 0.25, 0.5, 1, and 2 mg (equiv to Klonopin rapidly disintegrating tablets)
KALI LABORATORIES
Liothyronine injection 10 mcg/mL in 1 mL vials (equiv to Triostat injection)
PHARMAFORCE
Ceftriaxone injection 1 g/50 mL and 2 g/50 mL, packaged in galaxy single-dose plastic containers (equiv to Rocephin injection)
BAXTER
Zidovudine tablets 300 mg (equiv to Retrovir)
ROXANE, RANBAXY, AUROBINDO PHARMA
Advertisement
Related to this article
Will Carroll, Pharm.D., of Sutter Health says pharmacy is often handed strategy to execute instead of shaping it, and must show value in C-suite terms.
Ty Gluckman, M.D., says undertesting and undertreatment are the biggest gaps in lipid care and calls on leaders to invest in cardiovascular prevention.
Ty Gluckman, M.D., says the 2026 dyslipidemia guideline brings back risk-based LDL goals, and clinical inertia, not access, is now the biggest barrier.
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B financial workhorse.
Robotic lobectomies grew from 49% to 70% of cases from 2020 to 2024 as access and training expanded, says Staci Beamer, M.D., of HonorHealth.
AI analyzes single-lead ECGs from sleep studies to predict atrial fibrillation, heart failure, and mortality risk, enabling scalable cardiovascular disease screening.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Heart data in sleep study predicts atrial fibrillation, heart failure years in advance
2
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
3
For bronchiectasis, a new era of guideline-guided care | CHEST 2026
4
Staci E. Beamer, M.D., on the rise of robotic lung surgery | CHEST 2026
5